Other equities research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Compugen from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Cantor Fitzgerald started coverage on shares of Compugen in a report on Wednesday, January 15th. They issued an “overweight” rating and a $10.00 price objective on the stock. Finally, BidaskClub upgraded shares of Compugen from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 3rd. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Compugen presently has a consensus rating of “Buy” and an average price target of $8.42.
NASDAQ CGEN opened at $6.60 on Friday. The stock has a market capitalization of $333.92 million, a price-to-earnings ratio of -13.20 and a beta of 2.74. Compugen has a 1-year low of $2.73 and a 1-year high of $6.70. The company has a debt-to-equity ratio of 0.07, a current ratio of 7.19 and a quick ratio of 7.19. The business’s fifty day moving average price is $5.92 and its 200-day moving average price is $4.68.
Institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN lifted its position in Compugen by 424.5% during the second quarter. Wells Fargo & Company MN now owns 7,526 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 6,091 shares in the last quarter. LPL Financial LLC bought a new stake in Compugen during the second quarter valued at about $43,000. D. E. Shaw & Co. Inc. purchased a new stake in Compugen in the second quarter worth about $45,000. Janney Montgomery Scott LLC purchased a new stake in Compugen in the third quarter worth about $68,000. Finally, State Street Corp purchased a new stake in Compugen in the third quarter worth about $92,000. 42.20% of the stock is currently owned by institutional investors.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Featured Article: How To Calculate Debt-to-Equity Ratio
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.